Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New lung-saving strategy aims to cut deadly ARDS complications

NCT ID NCT07516665

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to use breathing machines for people with severe lung failure (ARDS). The goal is to reduce lung damage by using very gentle breaths and adding a machine that helps remove carbon dioxide from the blood. About 290 adults on breathing machines for less than a week will be enrolled. The main outcome is survival and fewer days on the ventilator at day 30.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 290 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Intubation and Invasive mechanical ventilation ≤ 7 days 2. Presence of all of the following conditions for ≤48 hours: * 80 ≤ PaO2/FiO2 ≤300 with PEEP \>5 cmH2O * Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules * Respiratory failure not fully explained by cardiac failure or fluid overload 3. One of the following criteria (with Vt set at 6 mL/kg PBW): * DeltaP ≥15 cm H2O OR * Ventilatory ratio ≥2.2 4. Signed Informed consent from a close relative or surrogate or a family member. According to the specifications of emergency inclusion, randomization without the close relative/surrogate consent could be performed if the patient is unable to give his/ger consent and when the close relative/surrogate/family member are absent. Close relative/surrogate/family member consent will be asked as soon as possible after randomization. The patient will be asked as soon as possible to give his/her consent for the continuation of the trial when his/her condition will allow. 5. Social security registration (AME excluded) Exclusion Criteria: 1. Age \<18 years 2. Pregnancy or breastfeeding 3. Catheter access to femoral vein or jugular vein impossible 4. Expected duration of mechanical ventilation \< 48 hours 5. Chronic restrictive or obstructive (COPD) respiratory insufficiency with home ventilation or oxygen therapy 6. Currently receiving ECLS therapy 7. Severe cardiac failure or ongoing acute coronary syndrome 8. Heparin-induced thrombocytopenia 9. Severe underlying pre-existing condition with expected six-month mortality \>50% 10. Contraindication for systemic anticoagulation (including platelet count \<50G/L) 11. Patient moribund, decision to limit therapeutic interventions 12. Acute brain injury or irreversible neurological pathology 13. Bone marrow transplantation within the last 1 year 14. Actual body weight exceeding 1 kg per centimeter of height 15. Prior enrolment in the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome (ARDS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.